Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

First NK Cell Therapy Approval Expected By 2028 Says Kuick Research In Its New Research Study On Global NK Cell Therapy ...

NIH trial shows new form of TIL therapy effective against colon, rectum, pancreas, and bile duct tumors.

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...